Abstract
Thymidylate synthase (TS) is a key enzyme in DNA synthesis and is inhibited by metabolites of the chemotherapeutic agent 5-fluorouracil (5FU). Nuclear expression of TS in human tissue in vivo has not been characterised and its clinicopathological correlates in malignancy are unknown. 52 cases of primary colorectal carcinoma (CRC) and 24 cases of matched metastatic carcinoma were studied immunohistochemically using the monoclonal antibody TS106. The degree of nuclear TS immunostaining correlated closely with levels of TS mRNA expression amongst 10 CRCs studied. Strong nuclear immunostaining was seen in normal basal crypt colonocytes and germinal centre cells, and in a varying proportion of adenocarcinoma cells. Amongst the primary carcinomas, higher TS nuclear expression was associated with prominent extracellular mucin production and right-sided location. Higher TS nuclear expression also showed a significant association with poorer response to protracted venous infusional 5FU therapy. There was no clear association between TS nuclear expression and Ki67 or p53 expression assessed immunohistochemically. There was a strong positive correlation between TS nuclear expression in primary and metastatic CRC but the latter generally showed higher expression than matched primary tumour tissue. These findings confirm the nuclear expression of TS protein in human cells in vivo and provide new insight into how such expression may relate to the behaviour of CRCs. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F and Sobrero A (1999) Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760–1770
Aschele C, Debernardis D, Tunesi G, Maley F and Sobrero A (2000) Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6: 4797–4802
Bikfalvi A (1995) Significance of angiogenesis in tumour progression and metastasis. Eur J Cancer 31A: 1101–1104
Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A and Poston G (1996) p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 22: 181–185
Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB and Boland CR (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117: 123–131
Chu E, Cogliate T, Copur SM, Borre A, Voeller DM, Allegra CJ and Segal S (1996) Identification of in vivo target RNA sequences bound by thymidylate synthase. Nucl Acid Res 24: 3222–3228
Chu E, Copur SM, Chen TM, Khleif S, Voeller DM, Mizunuma N, Patel M, Maley GF, Maley F and Allegra CJ (1999) Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol 19: 1582–1594
De Both NJ, Vermey M, Groen N, Dinjens WN and Bosman FT (1997) Clonal growth of colorectal-carcinoma cell lines transplanted to nude mice. Int J Cancer 72: 1137–1141
Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I and Ragnhammar P (1997) Immunohistochemical determination of thymidylate synthase in colorectal cancer – methodogical studies. Eur J Cancer 33: 2278–2281
Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N and Iacopetta B (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355: 1745–1750
Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A and Aherne GW (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75: 903–909
Gilmore PM, Church SW, Danenberg KD, Danenberg PV, Salonga D, Park JM and Johnston PG (1998) The development and optimization of a quantitative RT-PCR technique from formalin-fixed and paraffin-embedded (FFPE) tissues, using the thymidylate synthase gene as a target [abstract]. Proc Am Soc Clin Oncol 17: 2159
Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A and Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13: 89–94
Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA and Joensuu H (2000) Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119: 921–928
Horikoshi T, Danenberg KD, Stadlbauer TH, Volkenandt M, Shea LC, Aigner K, Gustavsson B, Leichman L, Frosing R and Ray M (1992) Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 52: 108–116
Jodrell DI, Stewart M, Aird R, Knowles G, Bowman A, Wall L, Cummings J and McLean C (2001) 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. Br J Cancer 84: 600–603
Johnston PG, Liang C-M, Henry S, Chabner BA and Allegra CJ (1991) Production and characterisation of monoclonal antibodies that localise human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res 51: 6668–6676
Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ (1994) The role of thymidylate synthase expression in prognosis and outcome in adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640–2647
Johnston PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407–1412
Larsson P-A, Carlsson G, Larsson L and Gustavsson B (1998) Determination of relative thymidylate synthase (TS) gene expression in tumour specimens and normal colon mucosa – relation to TS protein levels. GI Cancer 2: 293–299
Lee Y, Chen Y, Chang L-S and Johnson LF (1997) Inhibition of mouse thymidylate synthase promotor activity by the wild-type p53 tumor suppressor protein. Exp Cell Res 234: 270–276
Leichman L, Lenz HJ, Leichman CG, Groshen S, Danenberg K, Baranda J, Spears CP, Boswell W, Silberman H, Ortega A, Stain S, Beart R and Danenberg P (1995) Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 31A: 1306–1310
Lenz H-J, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV and Leichman LP (1998a) p53 and thymidylate synthase expression in untreated stage II colon cancer: association with recurrence, survival and site. Clin Cancer Res 4: 1227–1234
Lenz H-J, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP and Leichman CG (1998b) p53 point mutation and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243–1250
McCarty KS Jr., Miller LS, Cox EB, Konrath J and McCarty KS Sr. (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antibodies. Arch Pathol Lab Med 109: 716–721
Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ and Johnston PG (2000) Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82: 560–567
Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S and Pinedo HM (1994) Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 12: 2035–2042
Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ and Pinedo HM (1995) Thymidylate synthase and drug resistance. Eur J Cancer 31A: 1299–1305
Poon P-P and Storms RK (1994) Thymidylate synthase is localized to the nuclear periphery in the yeast Saccharomyces cerevisiae. J Biol Chem 269: 8341–8347
Quirke P and Williams GT (1998) Minimum dataset for colorectal cancer histopathology reports. London, The Royal College of Pathologists (UK)
Ravaioli A, Bagli L, Zucchini A and Monti F (1998) Prognosis and prediction of response in breast cancer: the current role of the main biological markers. Cell Proliferation 31: 113–126
Revillion F, Pawlowski V, Hornez L and Peyrat JP (2000) Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer 36: 1038–1042
Rhee MS, Balinska M, Bunni M, Priest DG, Maley GF, Maley F and Galivan J (1990) Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells. Cancer Res 50: 3979–3984
Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322–1327
Samsonoff WA, Reston J, McKee M, O’Connor B, Galivan J, Maley G and Maley F (1997) Intracellular location of thymidylate synthase and its state of phosphorylation. J Biol Chem 272: 13281–13285
Sanguedolce R, Vultaggio G, Sanguedolce F, Modica G, Li Volsi F, Diana G, Guereio G, Bellanca L and Rausa L (1998) The role of thymidylate synthase levels in the prognosis of the treatment of patients with colorectal cancer. Anticancer Res 18: 1515–1520
Suzuki M, Okabe H, Tsukagoshi S, Kawai T, Fukushima M and Sato I (1998) Immunohistochemical investigation of thymidylate synthase in cervical cancer. Oncology 55: 564–568
Thomas DM and Zaleberg JR (1998) 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol 25: 887–895
Toft NJ and Arends MJ (1998) DNA mismatch repair and colorectal cancer. J Pathol 185: 123–129
van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HF and Peters GJ (2000) Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6: 1063–1072
Yamachika T, Nakanishi H, Inada K-I, Tsukamoto T, Kato T, Fukushima M, Inoue M and Tatematsu M (1998) A new prognostic factor for colorectal carcinoma, thymidylate synthase and its therapeutic significance. Cancer 82: 70–77
Zhang XD, Coventry BJ, Jamieson GG and Gill PG (1998) The utility of the proliferative index in pretreatment biopsy specimens of esophageal squamous cell carcinoma. Disease of the Esophagus 11: 215–220
Author information
Authors and Affiliations
Additional information
Data from this study were presented at the 179th Meeting of the Pathological Society of Great Britain and Ireland, held at Ninewells Hospital & Medical School, Dundee, UK.
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Wong, N., Brett, L., Stewart, M. et al. Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma. Br J Cancer 85, 1937–1943 (2001). https://doi.org/10.1054/bjoc.2001.2175
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2175
Keywords
This article is cited by
-
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent
Cancer Chemotherapy and Pharmacology (2023)
-
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy
The Pharmacogenomics Journal (2015)
-
Thymidylate synthase expression and p21WAF1/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy
Cellular Oncology (2014)
-
Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor
Virchows Archiv (2009)
-
Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial
British Journal of Cancer (2007)